Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.

MLA

Slade, Michael, et al. “Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.” Transplantation and Cellular Therapy, vol. 29, no. 12, Dec. 2023, p. 764.e1-764.e7. EBSCOhost, https://doi.org/10.1016/j.jtct.2023.09.014.

APA

Slade, M., Fiala, M. A., Kirchmeyer, M., King, J., Gao, F., Schroeder, M. A., Stewart, A. K., Stockerl-Goldstein, K., Chen, C., & Vij, R. (2023). Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial. Transplantation and Cellular Therapy, 29(12), 764.e1-764.e7. https://doi.org/10.1016/j.jtct.2023.09.014

Chicago

Slade, Michael, Mark A Fiala, Marie Kirchmeyer, Jeff King, Feng Gao, Mark A Schroeder, A Keith Stewart, Keith Stockerl-Goldstein, Christine Chen, and Ravi Vij. 2023. “Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.” Transplantation and Cellular Therapy 29 (12): 764.e1-764.e7. doi:10.1016/j.jtct.2023.09.014.